NovoMedix Presents New Preclinical Data on NMX2 at the 2022 American Heart Association (AHA) Scientific Sessions Meeting

/PRNewswire/ -- NovoMedix, LLC ("NovoMedix"), a biotechnology company developing novel, multi-pathway modulators for fibrosis and cancer, today announced the...

Related Keywords

Illinois ,United States ,San Diego ,California ,Chicago ,American ,Cathy Swindlehurst ,American Heart Association Scientific Session ,Linkedin ,Prnewswire Novomedix ,Heart Association Scientific Session ,Improves Metabolic Parameters ,Protects Cardiomyocytes Against Ischemic ,Novomedix ,